Fosun Pharma (01696.HK) released its interim performance results, with a net profit attributable to shareholders of $6.426 million, a decrease of 41.3% year-on-year.

Zh tng cijng APP xn, f ru ylio kj (01696.HK) fb jizh 2025 nin 6 yu 30 r zh li g yu yj, shuy 1.65 y miyun, tngb xijing 1.9%; mgngs yngrn yng zhn yl 642.6 wn miyun, tngb xijing 41.3%; mig jbn yngl 1.37 mi xin. According to Zhtng Finance and Economics APP, Furu Medical Technology (01696.HK) announced its performance for the six months ending on June 30, 2025, with a revenue of 165 million US dollars, a decrease of 1.9% year-on-year; the net profit attributable to the owners of the parent company was 6.426 million US dollars, a decrease of 41.3% year-on-year; and basic earnings per share were 1.37 US cents.